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Abstract  
Aim: To collect information about how people with acne make day-to-day decisions 
concerning the effectiveness of their treatment.   
Methods: Between May and August 2013, an optional question was embedded in 
the James Lind Alliance Acne Priority Setting Partnership’s online survey to collect 
treatment uncertainties. The question asked people with acne to ‘Tell us in your own 
words how you decide if your treatment has been effective’.    
Results: A total of 742 respondents specified at least one outcome or means of 
assessing change (outcome measure). Fewer spots was the most commonly cited 
outcome, identified by 272 respondents (36.7%). Other frequently mentioned 
outcomes were, in descending order: less redness (19.4%), reduction in spot size 
(12.1%) and less pain/discomfort (11.4%). Signs were much more commonly used 
than symptoms and surrogate outcomes such as changes in aspects of life quality 
were infrequently mentioned. Visual inspection of the skin was the most widely 
adopted outcome measure (16.3%).  
Conclusions: Although the most frequently used methods map well onto the 
outcome measures adopted in the majority of acne trials, namely physician-assessed 
changes in lesion counts and global acne severity, people with acne often take into 
account several factors that cannot be assessed by a third party at a single point in 
time. The minimal use of changes in psychosocial wellbeing and mood may reflect 
that these are regarded as secondary consequences of improvements in 
appearance. The robustness of these findings now requires independent evaluation. 
If confirmed, they could form the basis of a new patient-reported outcome measure.   
Key words: acne vulgaris, decision-making, self-assessment, treatment outcome  
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Introduction 
The most widely used methods for measuring treatment-related change in acne 
clinical trials are lesion counting and physician-assessed global acne severity (1, 2). 
The latter is typically measured using interval scales of low sensitivity such as the 
widely used five-point scale recommended by the US Center for Drug Evaluation and 
Research (3). Many different scales were developed before patient input into the 
reporting of outcomes and construction of outcome measures became widely 
recognised as fundamental aspects of best practice. Recent trials of acne therapies 
are more likely to include assessment of changes in health-related quality-of-life 
(QoL) but there is no consensus about which instrument should be employed; 
subsequently generic, dermatology-specific and acne-specific measures have been 
used by different investigators in different settings (4-6). Although the developers of 
acne- and dermatology-specific QoL instruments and a new patient-reported 
outcome measure (PROM) for acne have consulted patients (7-11), in the main, the 
final instruments were based on the most commonly mentioned clinical features of 
acne and/or impacts on everyday life. None sought to establish which of the clinical 
features and impacts identified are commonly employed by acne patients to make 
day-to-day decisions about treatment effectiveness.  
 
In contrast, this study set out with the sole aim of addressing the paucity of available 
information about ways people with acne (PwA) instinctively monitor how well their 
treatment is working. We use PwA throughout in preference to acne patients as 
many acne sufferers self-manage their condition and do not consult doctors (12,13).  
Within the UK, James Lind Alliance Priority Setting Partnerships (PSPs, 
http://www.jla.nihr.ac.uk/about-the-james-lind-alliance/) represent a well-established 
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National Institute of Health Research process that involves a data gathering exercise 
from both patients and professionals with the aim of identifying and subsequently 
prioritising through consensus unanswered questions about treatments for a 
particular condition. A total of 1,456 PwA took part in the Acne PSP together with 652 
healthcare and related professionals (14). The opportunity was taken to embed an 
additional research question within the PSP’s questionnaire to harvest treatment 
uncertainties with the implicit aim of identifying the most commonly used ways PwA 
decide if their treatment is working.   
 
Methods 
A single question designed to identify how PwA decide whether their treatment is 
working was identified in consultation with the COMET (Core Outcome Measures in 
Effectiveness Trials) Initiative and the editor of the UK Database of Uncertainties 
about the Effects of Treatment. Small groups of acne patients (n = 11) and clinical 
staff (n = 9) from two dermatology units in the UK were asked to review different 
wordings of the question. The most popular (12/20, 60%) was “Please tell us in your 
own words how you decide if your treatment has been effective”. The question was 
included in the online patient survey to harvest treatment uncertainties which was 
hosted on the Acne PSP website and promoted to PwA within and beyond the UK.   
 
Once the survey closed, responses were downloaded into ExcelTM. A simplified 
thematic analysis of the extracted data was performed by one investigator (AE) to 
ensure consistency in interpretation based on the method of Braun and Clarke (15) 
whereby data are manually organised into meaningful groups. This approach 
enabled identification of all ways used by PWA to decide if their treatment was 
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working. Codes were then used to group responses into candidate themes and sub-
themes by one author (AE) and checked by two independent authors (HW and KW). 
Once all sub-themes had been identified and verified, responses relating to each 
were enumerated. For analysis, the number of respondents who described a 
symptom, sign or impact or a change in the same parameter were combined (e.g. 
intensity of redness, skin less red).   
 
Ethical approval to embed a research question within the PSP harvesting survey was 
obtained from West of Scotland REC4 (reference number 13/WS/0015). NHS 
governance approval was obtained from Harrogate and District NHS Foundation 
Trust.  
 
Results 
Demographics 
A total of 897 people responded to the outcomes question, representing 61.6% of 
PwA who took part in the harvesting survey. Of these, 742 PwA (84.2% female) 
identified at least one outcome or outcome measure and their responses were 
included in the analysis. The remaining responses were excluded as they did not 
contain any usable outcomes related information. Almost half of all respondents 
(46.8%) were aged 16 to 24 and the age distribution mirrored what would be 
expected for acne. A quarter (27.4%) lived outside the UK and one in five (20.5%) 
were non-white (Figure 1). Within the UK, responses were obtained from 102 of 121 
postcode areas. Demographic data for the excluded subjects were broadly similar 
and there were no significant demographic differences between the included and 
excluded populations.   
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Themes 
Three distinct themes were identified: signs and symptoms, impacts and ways of 
assessing change. Quotations illustrating these themes are shown in Table 1. They 
were not mutually exclusive. Among the 742 respondents, only 38 mentioned 
impacts (5.1%) whereas 507 (68.3%) mentioned at least one symptom or sign which 
they expected treatment to ameliorate. Eighty-six respondents (11.6%) mentioned no 
specific signs, symptoms or impacts e.g. using phrases such as general clarity of 
skin, skin condition, feel better about my appearance, etc. The majority of PwA (521, 
70.2%) used one or two criteria to assess treatment effectiveness. Ninety-six people 
mentioned three, 35 mentioned four and 14 mentioned five or more criteria. 
 
Sub-theme: signs and symptoms 
A summary of signs and symptoms mentioned by at least 2% of respondents is 
shown in Figure 2. Less commonly mentioned signs and symptoms are shown in 
Supplementary Table 1. Reduction in the number of spots, the most frequently 
mentioned outcome, was unambiguously reported by 272 responders (36.7%). A 
further 40 (5.4%) said they expected treatment to reduce the numbers of a specific 
type of spot. In addition, 61 people (8.2%) stated that they would want treatment to 
reduce the number of new spots or prevent new spots forming and 39 (5.2%) 
identified fewer breakouts or acne flares. Both breakout and flare suggest a crop of 
new spots occurring simultaneously although, from the context, some respondents 
also used these terms to mean a single lesion.    
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The second most commonly mentioned sign was redness or inflammation, reported 
by 144 people (19.4%). The only other sign mentioned by >10% of respondents was 
spot size (90, 12.1%). Aspects of scarring were identified as important by 41 
respondents (5.5%) and oiliness of skin by 37 (5.0%). Skin texture was identified by 
49 people (6.6%) and overall appearance by 41 (5.5%). The most commonly 
mentioned symptom was pain, soreness or discomfort (85, 11.4%).  
 
Sub-theme: impacts  
The impact most frequently identified was level of confidence (22 people, 3.0%). 
Whilst most people wrote about confidence in general, some women (7, 0.94%) said 
they felt more comfortable, happier or more confident without make-up if treatment 
had been effective. Nine people (1.2%) mentioned effective treatment would alter 
how they feel about their skin or about themselves and seven (0.94%) said they were 
happier or felt better when their treatment worked.  
 
A negative treatment impact (as opposed to an acne impact modulated by treatment) 
was the trade-off between efficacy and side effects. Sixteen people mentioned they 
would not consider a treatment to be effective if it deleteriously affected the condition 
of their skin. For example, one respondent commented “It's not really a great success 
if you eliminate spots, which can be concealed by make-up to a certain extent, but 
replace them with dry, red flaking skin that cannot be hidden.” 
 
Outcome measures 
The most frequently used ways of assessing change are shown in Figure 3. The 
most common way of detecting treatment effects was by looking at the skin and 
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noticing a difference in ‘spottiness’, clarity or general condition (121, 16.3%). Many 
respondents described using a mirror (45, 6.1%) or taking photographs (68, 9.2%) to 
monitor changes; one kept a video diary. Although the number of spots was the sign 
most people wanted treatment to address, only 46 (6.2%) clearly stated that they 
counted spots. Interestingly, 24 people (3.2%) said they didn’t count or didn’t think it 
was useful to do so.  For example, one respondent commented “It’s not the math of 
how many, but, how wonderful or how awful it [the skin] looks - qualitative, not 
quantitative”. Five people said they used a scale to assess improvement, one 
specifically to assess redness. Although 48 people (6.5%) used one or more aspects 
of how their skin felt as a means of measuring treatment efficacy, only 22 (3%) 
described in detail how they did this e.g. “It works if I can feel the bumps going down 
and the texture of my skin improve”.  
 
Frequency of assessment and time to achieve change was an important aspect. 
Some people checked their skin daily (36, 4.9%), others weekly or monthly (17, 
2.3%). Some (35, 4.7%) specified a deadline by which they expected to detect an 
improvement. This varied from 1-2 weeks to 3-5 months.  
 
Expectations of the degree of treatment effectiveness also varied amongst the 
respondents (Table 2). A good example was clear versus clearer skin; whilst 70 
people (9.4%) wanted clearer skin or an improvement in skin clarity, 51 (6.9%) 
expected their skin to be totally clear of spots in order to regard treatment as 
effective. The way responses were expressed suggested that most people had 
realistic expectations, using words like fewer, less or reduced in recognition that 
complete cure was unlikely. 
 9 
 
 
Word usage: signs and symptoms 
Acne lesions were most often referred to as spots (414 people, 55.8%), occasionally 
as pimples (26, 3.5%) or bumps (21, 2.8%) and uncommonly as blemishes (5, 0.7%), 
lesions (5, 0.7%), lumps (5, 0.7%) or zits (2, 0.3%). Specific lesion types were 
mentioned infrequently: cysts by 26 (3.5%), blackheads by 18 (2.4%), pus/pustules 
by 15 (2.0%) and whiteheads by nine people (1.2%). Various qualifying words were 
used to describe acneic skin more generally, the commonest being red (100 people, 
13.5%), painful (46 people, 6.2%), inflamed (44 people, 5.9%) and bad (27 people, 
3.6%). Sebum was most commonly referred to as oil (25 people, 3.4%) and less 
frequently as grease (11 people, 1.5%). Scar or scarring (42 people, 5.7%) was used 
more commonly than mark (8 people, 1.1%) or splotch (2 people, 0.3%) and it was 
sometimes difficult to tell if people were describing scars or macules (e.g. “red 
mark”).  
 
Word usage: outcome measures 
A variety of words and phrases were used to describe change or how change was 
assessed. The most common way of describing change was as less or lessening 
(123 people, 16.6%), followed by clearer or clearing (103 people, 13.9%). The word 
“how” was used by 153 respondents (20.6%) as a quantitative (e.g. how red, how 
many pimples) or qualitative measure (e.g. how I felt). The most frequently used 
verbs to describe how change was assessed were look/looking (192 people, 25.9%) 
and see/seeing (159 people, 21.4%).  
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Discussion  
A recent systematic review, across all disease categories, of studies that sought to 
determine which outcomes to measure in future clinical trials found no published 
evidence that PwA have been consulted on this important topic (16). In contrast to 
the numerous studies which have sought to determine what bothers people about 
having acne, we are not aware that any have previously asked patients about the 
changes they would expect to see as a result of treatment or how they would assess 
these.   
 
The Acne PSP provided a legitimate platform to ascertain how a large number of 
PwA decide if their treatment is working. The number of spots or, perhaps more 
correctly, extent of spottiness was by far the most frequently mentioned outcome 
PwA wanted treatment to address.  In general, they assessed how their skin looked 
in the mirror, in a photograph or to others rather than by counting spots to monitor 
treatment effects; methods that can be likened to global severity grading. However, 
respondents used a much broader range of criteria to assess treatment efficacy than 
are captured by lesion counts and acne severity grades which together represent the 
most commonly used measurements in current clinical trials. Their responses show 
that PwA recognise the insidious nature of acne and incorporate this into their 
assessments of treatment effect. For example, they notice that the number of new 
spots decreases, gaps between breakouts lengthen, the areas of affected skin 
become smaller, the size, depth, prominence or type of spot changes and spots heal 
more quickly when treatment is effective. These changes cannot be easily captured 
by existing physician administered grading scales or by assessments made at fixed 
points in time, as in a clinical trial. Whilst standardised digital imaging techniques now 
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under development (17) may provide a potential novel and improved method to 
capture more subtle treatment effects, the findings suggest that patient-reported 
symptoms and signs should be considered within future clinical trials.      
 
The second most common feature of acne which respondents used as a measure of 
treatment effectiveness was reduction in the degree of inflammation, typically 
described as redness. Many acne severity scales ignore the persistent inflammation 
associated with healing lesions (macules) and scars. Lack of response to oral and 
topical acne medications has been used to justify the exclusion of macules and scars 
(which can be numerous) from lesion counts and severity grades. However, it is now 
recognised that several acne therapies including physical ones have a positive 
impact on both scarring and macules (18, 19), and it may be timely to devise new 
grading methods to reflect this.    
 
Skin feeling better (less pain, soreness or discomfort) was the third most frequently 
mentioned outcome and uncomfortable skin was the most commonly mentioned 
symptom. Treatment effects on how the skin feels from within are not captured by 
counting spots or acne severity grading scales and are invariably not assessed in 
acne trials. Respondents often used one or more aspects of their complexion such as 
the overall appearance or condition/texture/tone of their skin as a measure of 
treatment effectiveness. There was considerable variation in how people did this 
ranging from a quick glance in the mirror to a standardised daily assessment regimen 
that included both looking and feeling. We are not aware of any validated scales 
which would enable subjects to rate the quality of their complexion or how their skin 
feels within a clinical trial.     
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Whilst frequency of reporting is not necessarily a reliable indicator of importance, we 
applied an arbitrary cut-off of 2% of respondents to identify outcomes which might be 
important for those developing novel outcome measures. Using this cut-off, reduction 
in skin oiliness also ranked among the criteria which future trial investigators should 
perhaps include, especially since more acne treatments are now able to address this.  
 
Because the Acne PSP was based in England, most participants were white and 
lived in in the UK. We recognize that linguistic issues may have meant that 
respondents for whom English was a second language may have interpreted the 
research question somewhat differently. Unexpectedly, there was significant gender 
bias amongst the respondents with females outnumbering males by more than four 
to one. Some of the ways in which outcomes were assessed such as need for make-
up to cover spots were mainly applicable to women. Apart from these, there was no 
evidence that males and females use different ways of assessing treatment 
effectiveness.  
 
We examined word usage to find out which words or phrases were most commonly 
used to describe symptoms and signs or change as this information could be useful 
when devising new PROMs. We found that many more respondents used the word 
spot than any other term for an acne lesion, possibly reflecting our own usage of this 
term in the harvesting survey into which the outcomes question was embedded. In 
contrast, a recent study in 48 patients aged 12 to 50 years from five US cities found 
that the most commonly used words to describe lesions were acne, pimples and zits 
(11). However, another US study conducted 10 years earlier, which also looked at 
word usage by patients when devising an acne specific QoL instrument, utilized 
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bump in the final questionnaire (9). When responses to the outcomes question from 
the USA and Canada were analyzed separately (n = 111), it was found that fewer 
respondents used the term spot (33.3%) than in the rest of the sample (66.6%). 
Further study of word usage by PwA is needed to inform the language used in 
PROMs. It may be that national differences and trends in word usage over time 
preclude the use of a universal terminology.   
 
The information obtained from this international study provides a valuable insight into 
the ways PwA monitor treatment effectiveness. It has shown that widely used 
outcome measures including lesion counting and global severity assessments 
capture some of the signs of acne which PwA want their treatment to address. 
However, PwA employ a much wider range of criteria, including clinical features 
which are not included within the commonly used acne-specific and dermatology-
specific health-related QoL questionnaires or a new PROM (Table 3). Many of the 
aspects identified in this study could not be measured by a third party, but could form 
the basis of one or more novel PROMs. Psychosocial impacts were rarely used by 
PwA to assess treatment efficacy suggesting that inclusion of instruments to 
measure these in acne trials may not always be of value.  
 
These preliminary findings, if confirmed by others especially in predominantly non-
white populations and in males, might be useful to the Acne Core Outcomes 
Research Network, which is seeking to develop a minimum set of consensus-derived 
outcome measures for global adoption in future acne trials (see 
http://sites.psu.edu/acnecoreoutcomes/). They suggest that greater emphasis should 
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be placed on participant as opposed to physician-rated assessment of symptoms and 
signs.   
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Table 1.  Quotations from patients relating to major themes 
Signs Symptoms Impacts Ways of 
assessing change 
“Size and area of 
face covered with 
spots.” 
“When I no longer 
have sore spots on 
my face I feel it is 
improving.” 
 
“If I feel confident 
to go out without a 
full face of make up 
on.” 
“Eyeball my skin 
condition.” 
“Dramatic reduction 
in number of spots 
and size and colour 
of spots.” 
“How 
uncomfortable it 
feels when I touch 
it.” 
“…allow me to do 
sports without 
worrying about 
showing off my skin 
to others.” 
“Nothing too 
accurate, just by 
looking and feeling 
every day.” 
“’If I get less 
breakouts, and my 
spots decrease in 
size and don't 
leave me with 
hyper-
pigmentation.” 
“If I can eat and 
smile without pain.” 
“How happy or 
otherwise I feel 
when I look at my 
face in the mirror.” 
“Whether my spots 
heal more quickly 
than normal.” 
 
“If the scars start to 
fade & I get my 
natural complexion 
back.” 
 
“Feeling less 
discomfort from 
deep spots.” 
“I rate it more by 
the psychological 
impact i.e. how 
much it bothers me 
mentally.” 
“Just generally 
looking at the 
affected areas to 
see how pimply 
and angry they 
look.” 
“If my skin in less 
oily and I’m not 
having as many 
spots.” 
“If my face doesn’t 
hurt it’s always 
better.” 
“When I could go 
out without thinking 
people could only 
see the spots, not 
me.” 
“I .. use my clean 
hands to feel the 
surface of my face 
to see if the bumps 
have gone down.” 
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Table 2.  Different expectations of treatment outcomes 
Nothing less than clear skin Better than it was before 
“When the pimples are gone.” “Quite simply less spots and less large.” 
“Spotless.” “I can usually just tell by areas clearing 
up or not.” 
“….cleared the spots completely and 
worked quickly.” 
“When the spots start to clear.”” 
“If they disappear and don’t come back.” “If there are fewer, less obvious spots”. 
‘Clear and comfortable skin or not.  
Simple.” 
“If the spots have lightened 
considerably.” 
“If my acne is gone it’s effective, if I still 
get pimples it's not.” 
“When I feel less bumps on my skin.” 
“I'll consider my acne treated once my 
skin is completely clear.” 
“By an improvement in my skin I could 
see.” 
“I would expect my acne to be cured.” “If there are no real bad sore angry 
looking spots I'm happy. I can cope with 
that.” 
“It's quite easy to see if a treatment 
works or not. If I still have spots, that 
means it doesn't!” 
“I just look to see if there's a change in 
the density and amount of my impurities 
and uneven tones on my skin.” 
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Table 3.  Signs and symptoms included in the most widely used acne and dermatology specific health related quality of 
life questionnaires and a new patient-reported outcome measure for acne 
 
Acne signs and/or symptoms included in 
Acne-specific 
quality of life 
questionnaire: 
Acne-QOL (7)1 
 
Cardiff Acne 
Disability Index: 
CADI (20) 
 
 
 
Skindex-16 (21) 
 
 
 
Skindex-29 (21)1 
 
Dermatology Life Quality 
Index: DLQI (22)/ 
Childrens’ DLQI (23)2 
 
Acne Symptom 
and Impact 
Scale: ASIS (11) 
Bumps No signs or 
symptoms 
included 
Skin hurting 
 
How itchy, sore, painful or 
stinging (itchy, scratchy, 
sore or painful in childrens’ 
version) 
Pimples 
Bumps full of pus Skin burns or stings 
 
 Blackheads 
Scabbing Skin itching 
 
Whiteheads 
Oily skin Skin being irritated Scars    
Skin sensitive 
 
Dark marks 
Skin bleeds Scabs 
 Oily skin 
Redness 
 
1These questionnaires also contain an item “worry about getting scars” which we considered to be an impact not a sign.   
 
2These four symptoms are included within a single item.
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Figure Legends 
 
 
Figure 1: Participant demographics. 
(a) Age distribution, (b) Ethnicity, (c) Location.  
 
 
 
Figure 2.  Sign, symptom and impact-related sub-themes identified by at least 
2% of respondents.   
 
 
 
Figure 3.  Ways of assessing change identified by at least 2% of respondents.   
Make-up was used as a measure of treatment success in several ways: amount used 
(14), no longer needing to use it (9), confident without it (7), visibility of spots through 
it (4), time taken to apply it (2). Responses describing use of a mirror or taking photos 
were not included in the looking and seeing category. Comments from others 
included both solicited and spontaneous ones.   
  
